荣昌生物上半年亏损4.5亿,经营现金流仍吃紧!核心产品BD交易获超5亿首付

时代周报
Aug 23

2022年以来,在经历连续三年半年报亏损且亏损不断扩大后,荣昌生物(688331.SH)在2025年上半年亏损大幅缩窄。8月22日,荣昌生物公布2025年半年报,公司营业收入为10.98亿元,同比上升48.02%;归母净利润亏损4.50亿元,同比去年上半年亏损7.80亿元有所减少;扣非净利润亏损4.46亿元,同比去年上半年亏损7.94亿元有所减少;经营现金流净额为-2.46亿元,同比去年上半年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10